Last reviewed · How we verify
Adenocard (ADENOSINE)
Adenocard (Adenosine) is a small molecule adenosine receptor agonist developed by Astellas, targeting the adenosine receptor A3. It is an FDA-approved medication for myocardial perfusion imaging adjunct and paroxysmal supraventricular tachycardia since 1989. Adenocard is off-patent with 15 generic manufacturers, making it widely available. Key safety considerations include potential for hypotension, bronchospasm, and heart block. As an off-patent medication, its commercial status is largely driven by generic competition.
At a glance
| Generic name | ADENOSINE |
|---|---|
| Sponsor | Astellas Pharma |
| Drug class | Adenosine Receptor Agonist [EPC] |
| Target | Adenosine receptor A3 |
| Modality | Small molecule |
| Therapeutic area | Neuroscience |
| Phase | FDA-approved |
| First approval | 1989 |
Approved indications
- Myocardial Perfusion Imaging Adjunct
- Paroxysmal supraventricular tachycardia
Common side effects
- Facial flushing
- Shortness of breath/dyspnea
- Chest pressure
- Nausea
- Headache
- Lightheadedness
- Numbness
- Sweating
- Palpitations
- Chest pain
- Dizziness
- Tingling in arms
Serious adverse events
- Prolonged asystole
- Ventricular fibrillation
- Ventricular tachycardia
- Atrial fibrillation
- Torsade de Pointes
- Seizure activity/grand mal seizures
- Loss of consciousness
- Bronchospasm
- Bradycardia
- Transient increase in blood pressure
Drug interactions
- carbamazepine
- gatifloxacin
Key clinical trials
- Adenosine 2A Receptor Antagonism and AIH in ALS (PHASE1,PHASE2)
- Testing the Combination of Anti-cancer Drugs, Tovorafenib Plus Rituximab, in Patients With Hairy Cell Leukemia (PHASE1,PHASE2)
- The Multicenter Stress Cardiac Magnetic Resonance Quantitative Perfusion Imaging in the United States Study (NA)
- Study of AZD4956 as Monotherapy and in Combination With Anti-Cancer Agents in Participants With Advanced/Metastatic Homologous Recombination Deficient Solid Tumours (PHASE1,PHASE2)
- Single-Center Phase II Double-Blind Trial of SAMe to Prevent Liver Cancer in MASLD-Related Cirrhosis (PHASE2)
- Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial) (PHASE2)
- A Study to Describe the Diagnosis, Anti-Cancer Treatment and Clinical Outcome in Patients With Newly Diagnosed Breast Cancer in Latin America
- CompassHER2-pCR: Decreasing Chemotherapy for Breast Cancer Patients After Pre-surgery Chemo and Targeted Therapy (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Adenocard CI brief — competitive landscape report
- Adenocard updates RSS · CI watch RSS
- Astellas Pharma portfolio CI